SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Sharck Soup
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sharck who wrote (2279)9/28/2000 7:53:38 AM
From: 2MAR$  Read Replies (1) of 37746
 
Myriad Genetics/Cancer Test -2: Based On Genetic Makeup

SALT LAKE CITY (Dow Jones)--Myriad Genetics Inc. (MYGN) launched the Colaris
predictive medicine test for hereditary predisposition to colon cancer.
In a press release Thursday, the biopharmaceutical company said the test
will be used to assess an individual's risk of colon cancer based on genetic
makeup.
The company first announced the test Aug. 17.
Company Web site: myriad.com
-Freddy Sebastian; Dow Jones Newswires; 201-938-5400

(END) DOW JONES NEWS 09-28-00
07:49 AM
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News